These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33734912)

  • 1. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug.
    Chrysant SG
    Expert Opin Drug Saf; 2021 Jun; 20(6):635-640. PubMed ID: 33734912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
    Tobin JV; Zimmer DP; Shea C; Germano P; Bernier SG; Liu G; Long K; Miyashiro J; Ranganath S; Jacobson S; Tang K; Im GJ; Sheppeck J; Moore JD; Sykes K; Wakefield J; Sarno R; Banijamali AR; Profy AT; Milne GT; Currie MG; Masferrer JL
    J Pharmacol Exp Ther; 2018 Jun; 365(3):664-675. PubMed ID: 29643251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.
    Ruiz-Torres MP; Griera M; Chamorro A; Díez-Marqués ML; Rodríguez-Puyol D; Rodríguez-Puyol M
    Cardiovasc Res; 2009 Apr; 82(1):125-32. PubMed ID: 19126601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
    Brockunier L; Stelmach J; Guo J; Spencer T; Rosauer K; Bansal A; Cai SJ; Chen N; Cummings J; Huang L; Johnson T; Levesque S; Luo L; Maloney K; Metzger J; Mortko C; Ortega K; Pai LY; Pereira A; Salituro G; Shang J; Shepherd C; Sherrie Xu S; Yang Q; Cui J; Roy S; Parmee E; Raghavan S
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127574. PubMed ID: 32980512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
    Bénardeau A; Kahnert A; Schomber T; Meyer J; Pavkovic M; Kretschmer A; Lawrenz B; Hartmann E; Mathar I; Hueser J; Kraehling JR; Eitner F; Hahn MG; Stasch JP; Sandner P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2363-2379. PubMed ID: 34550407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy.
    Ataei Ataabadi E; Golshiri K; Jüttner A; Krenning G; Danser AHJ; Roks AJM
    Hypertension; 2020 Oct; 76(4):1055-1068. PubMed ID: 32829664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nitric oxide/soluble cyclic guanylase/cyclic guanosine monophosphate pathway is involved in the cardiovascular effects of a novel α1- and β-adrenoceptor antagonist.
    Kubacka M; Mogilski S; Bednarski M; Raźny K; Sapa J; Waszkielewicz AM; Marona H; Filipek B
    Pharmacology; 2014; 94(5-6):287-95. PubMed ID: 25531925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive Effects of a Soluble Guanylate Cyclase Stimulator.
    Bykov VV; Birulina YG; Nosarev AV; Vengerovskii AI; Udut VV
    Bull Exp Biol Med; 2022 Nov; 174(1):33-36. PubMed ID: 36437315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
    Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasorelaxing and antihypertensive effects of 7,8-dihydroxyflavone.
    Huai R; Han X; Wang B; Li C; Niu Y; Li R; Qu Z
    Am J Hypertens; 2014 May; 27(5):750-60. PubMed ID: 24317273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the role of soluble guanylate cyclase in blood pressure regulation.
    Buys E; Sips P
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):135-42. PubMed ID: 24419369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.